U.S., Sept. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07794579) titled 'A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity' on Aug. 26.
Brief Summary: This study will evaluate the efficacy and safety of orforglipron in participants with overweight and assess whether it helps reduce the future risk of obesity-related conditions, including type 2 diabetes, hypertension, and dyslipidemia, and progression to class 1 obesity.
Study Start Date: Sept., 2026
Study Type: INTERVENTIONAL
Condition:
Overweight
Prediabetic State
Prehypertension
Obesity, Abdominal
Intervention:
DRUG: Orforglipron
Administered orally...